Document Detail


Therapeutic concepts in succinate semialdehyde dehydrogenase (SSADH; ALDH5a1) deficiency (gamma-hydroxybutyric aciduria). Hypotheses evolved from 25 years of patient evaluation, studies in Aldh5a1-/- mice and characterization of gamma-hydroxybutyric acid pharmacology.
MedLine Citation:
PMID:  17457693     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We overview the pathophysiological bases, clinical approaches and potential therapeutic options for succinate semialdehyde dehydrogenase (SSADH; EC1.2.1.24) deficiency (gamma-hydroxybutyric aciduria, OMIM 271980, 610045) in relation to studies on SSADH gene-deleted mice, outcome data developed from 25 years of patient evaluation, and characterization of gamma-hydroxybutyric acid (GHB) pharmacology in different species. The clinical picture of this disorder encompasses a wide spectrum of neurological and psychiatric dysfunction, such as psychomotor retardation, delayed speech development, epileptic seizures and behavioural disturbances, emphasizing the multifactorial pathophysiology of SSADH deficiency. The murine SSADH-/- (e.g. Aldh5a1-/-) mouse model suffers from epileptic seizures and succumbs to early lethality. Aldh5a1-/- mice accumulate GHB and gamma-aminobutyric acid (GABA) in the central nervous system, exhibit alterations of amino acids such as glutamine (Gln), alanine (Ala) and arginine (Arg), and manifest disturbances in other systems including dopamine, neurosteroids and antioxidant status. Therapeutic concepts in patients with SSADH deficiency and preclinical therapeutic experiments are discussed in light of data collected from research in Aldh5a1-/- mice and animal studies of GHB pharmacology; these studies are the foundation for novel working approaches, including pharmacological and dietary trials, which are presented for future evaluation in this disease.
Authors:
I Knerr; P L Pearl; T Bottiglieri; O Carter Snead; C Jakobs; K M Gibson
Related Documents :
237623 - Specificity of gamma-glutamyl cyclotransferase.
6317133 - Two distinct interactions of barbiturates and chlormethiazole with the gabaa receptor c...
6033603 - Kinetic analysis of the oxidation of palmitate-1-14c in man during prolonged heavy musc...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2007-04-24
Journal Detail:
Title:  Journal of inherited metabolic disease     Volume:  30     ISSN:  1573-2665     ISO Abbreviation:  J. Inherit. Metab. Dis.     Publication Date:  2007 Jun 
Date Detail:
Created Date:  2007-06-01     Completed Date:  2007-08-17     Revised Date:  2007-12-03    
Medline Journal Info:
Nlm Unique ID:  7910918     Medline TA:  J Inherit Metab Dis     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  279-94     Citation Subset:  IM    
Affiliation:
Children's and Adolescents' Hospital, University of Erlangen-Nuremberg, Erlangen, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amino Acid Metabolism, Inborn Errors / genetics*,  physiopathology
Animals
Anticonvulsants / pharmacology,  therapeutic use
Disease Models, Animal
Humans
Mice
Mice, Knockout
Phenotype
Sodium Oxybate / urine*
Succinate-Semialdehyde Dehydrogenase / deficiency*,  genetics
gamma-Aminobutyric Acid / metabolism
Grant Support
ID/Acronym/Agency:
R01 NS40270/NS/NINDS NIH HHS
Chemical
Reg. No./Substance:
0/Anticonvulsants; 502-85-2/Sodium Oxybate; 56-12-2/gamma-Aminobutyric Acid; EC 1.2.1.24/Succinate-Semialdehyde Dehydrogenase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Regionally selective decreases in cerebral glucose metabolism in a mouse model of phenylketonuria.
Next Document:  Transferrin hypoglycosylation in hereditary fructose intolerance: using the clues and avoiding the p...